AstraZeneca Pharmaceutical’s naloxegol or Moventig, is now available on the Swedish market, the first country in Europe since approval for the European market was granted in 2014.

In mid- September 2014, naloxgel was approved for use in the U.S. under the name Movantik. It was launched on the US market this week.

Naloxegol is intended for use by adults with constipation as a result of opioidbehandling, where the purge had not had sufficient impact. The drug is an oral treatment to be taken once a day. It works by inhibiting opioidreceptorerna in the intestine.

 Source: Life Science Sweden